Our Targeted Anti c-Kit Antibody
Briquilimab (formerly JSP191) is a targeted anti c-Kit monoclonal antibody designed to deplete mast cells and diseased stem cells as well as enable safer and more effective curative hematopoietic stem cell transplants and stem cell gene therapies.
Jasper is studying briquilimab across multiple diseases. Briquilimab is currently being studied as a therapeutic for chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID).